Drug development, especially in its clinical stages is very expensive and very risky, since the great majority of candidates that are evaluated in clinical trials fail. The two principal technical risks in drug development are efficacy and safety, and the information derived for IND filings prior to clinical stages plainly does not adequately predict efficacy and safety in Man, evidenced by the large number of late stage failures.

e-Therapeutics provides a different approach to de-risking molecules for efficacy and safety, based on its ability to evaluate quantitatively the net effect of a molecule on target cell types, and on non-target, normal cell types.

This evaluation capability is used as a decision support tool by investors prior to investment or to guide investment decisions, and pharmaceutical companies prior to investing their resources in clinical programmes for candidates developed in-house or before in-licensing candidates.

e-Therapeutics evaluation is also used to help determine the mode of action of molecules, to identify appropriate positioning against competitive drugs, and to identify and characterise possible drug interactions. e-Therapeutics’ evaluation has also been applied to all the molecules with which a specific candidate is expected to have to compete, in order to provide a basis for de-risking the molecule’s competitive proposition.

Please contact us if you wish to take advantage of these capabilities in your own activities.